All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.

2018-03-21T10:01:56.000Z

FDA approves brentuximab vedotin with combination chemotherapy for advanced stage classical HL

Mar 21, 2018
Share:

Bookmark this article

On 20 March 2018, the US Food and Drug Administration (FDA) granted approval of brentuximab vedotin in combination with chemotherapy, for the treatment of adults with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL).

The FDA approval was based on the successful results from the multicenter, open-label, randomized ECHELON-1 phase III clinical trial (NCT01712490). In this study, brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine (A+AVD) was compared to AVD plus bleomycin (ABVD), as a regimen for advanced stage cHL patients. Superior efficacy of A+AVD was reported with a significantly lower combined risk of progression, as compared to ABVD.

The FDA had granted this application Priority Review and Breakthrough Therapy designation. According to Richard Pazdur, Director of the FDA Oncology Center of Excellence “Today’s approval represents an improvement in the initial treatment regimens of advanced HL that were introduced into clinical practice more than 40 years ago”.

In an interview we conducted at ASH 2017, Atlanta, GA, Professor Anas Younes from the Weill-Cornell Medical College, discussed the ECHELON-1 results and how they impact the current standard of care for advanced-stage HL patients.

  1. FDA. FDA expands approval of Adcetris for first-line treatment of Stage III or IV classical HL in combination with chemotherapy. 2018 Mar 20. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm601935.htm [Accessed 2018 Mar 21]

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

HCPs, what is your preferred format for educational content on the Lymphoma Hub?
44 votes - 79 days left ...

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox